Articles tagged with Cancer Medication
Sandra Horning, a cancer survivor and renowned oncologist, will receive the Duane Roth Memorial Award for her pioneering work in developing new treatments for lymphoma. Her commitment to personalized therapies and holistic approaches to patient care has improved cancer treatment outcomes.
A new UTSA study has found a potential link between a medication used to prevent infections in cancer patients and the regeneration of sperm from stem cells. Researchers discovered that G-CSF, a drug commonly used to recover from chemotherapy and radiation treatments, can also help restore male fertility.
A study found that taking abiraterone acetate, a widely used prostate cancer drug, with a low-fat breakfast is as effective as taking it on an empty stomach, but at a significantly lower cost. The finding could save patients thousands of dollars per month.
A breakthrough trial at the University of Minnesota found that a new UMN-developed drug, eBAT, significantly improved the six-month survival rate for dogs with hemangiosarcoma (HSA) to approximately 70%. The study's results suggest potential for translation into human clinical trials.
Researchers found a previously unappreciated role for Abraxane in tumor immunology, suggesting ways to improve the drug and develop new combination treatments. Nab-paclitaxel enables macrophages to switch from immune-suppressing M2 cells back into M1 cells that amplify the body's effort to kill cancer cells.
Researchers created functional microtissue technology that mimics human drug responses, identifying effective anti-cancer drugs. The vascularized micro-tumor platform accurately targets both tumor cells and vessels, offering a breakthrough in cancer treatment
A new study reveals that short fragments of circular DNA encoding cancer genes are common in cancer cells and contribute to their diversity. The research suggests that tumors with these genes on circular DNA are more resistant to treatments, making them harder to treat.
Researchers propose that aspirin's anti-tumor effect is due to its ability to block platelet interaction with cancer cells. The study suggests that aspirin can curb tumor growth by reducing circulating platelets and their activity.
In a groundbreaking study, 16 patients with severe aplastic anemia were successfully treated using partially matched bone marrow transplants followed by chemotherapy. After stopping immunosuppressive drugs over a year after their transplants, all patients showed no evidence of the disease.
Scientists have identified a distinct cell population in tumours that inhibits the body's immune response to fight cancer. By targeting these cells, researchers hope to enhance the immune system's ability to attack cancer cells.
Thomas Gajewski, a pioneer in cancer immunotherapy, has received a $4.2 million grant to support his research on overcoming tumor resistance. His team is exploring new approaches, including drugs that enhance immune system function and the role of gut microbiota in cancer.
A new study found that 84% of patients with acute lymphocytic leukemia or their parents over-reported adherence to a regimen of 6-mercaptopurine, an oral maintenance therapy. Forgetfulness was the primary reason for non-adherence, and parental involvement improved adherence rates.
Researchers have developed a potential new anti-cancer drug class that simultaneously inhibits two key molecular targets to maximize therapeutic efficiency and safety. The dual-activity inhibitors target MYC-regulated factors PI3K and BRD4, effectively blocking cancer cell growth and metastasis.
A novel genetic defect in brain tumor cells has been identified by Yale researchers, which renders the cancers sensitive to a specific DNA repair mechanism. The team found that using an FDA-approved drug, olaparib, can cause a significant increase in brain tumor cell death.
Researchers found that long-term soy consumption improves tamoxifen's effectiveness and reduces breast cancer recurrence. However, starting soy intake after diagnosis increases the risk of cancer recurrence.
Researchers at SLU are working on a potential cure for hepatitis B, building on recent advances and partnering with experts in medicinal chemistry. The goal is to develop a new drug that can kill the virus, reducing levels to zero to cure patients.
The number of new therapeutic drugs approved by the FDA was significantly lower in 2016 compared to previous years, with only four cancer drugs receiving approval. Delays in pharmaceutical manufacturing plants and a reduction in cancer drug approvals contributed to this trend.
Researchers used neutron crystallography to visualize the positions and movements of hydrogen atoms in a key enzyme from Helicobacter pylori, which causes stomach cancer. The study provides insights into the enzyme's structure and potential targets for new medications that selectively target H. pylori without harming useful bacteria.
Researchers at OHSU developed a method for quickly mapping single cell genomes, expanding the analysis of cancerous tumors and other diseases. This breakthrough enables precise targeting of cancer cells, offering new avenues for personalized medicine.
The CIViC knowledgebase is an open-access resource that allows anyone to contribute information on cancer mutations. Experts in the field curate and moderate submissions, providing a valuable resource for clinicians to identify important mutations and connect genetic errors with targeted drugs.
New cancer drugs have shown clinical benefit, but disparities in national health technology assessment outcomes hinder patient access. In the UK, prices for some common drugs increased by over 1000% between 2011 and 2016.
A new laboratory technique allows for the indefinite growth of healthy and diseased cells, offering possibilities for living biobanks, personalized medicine, and novel cancer research. The method, known as conditional reprogramming, can grow million new cells in a week without genetic modification.
Researchers at Mount Sinai discovered that specific signals in primary tumors induce dormant cancer cells that can evade chemotherapy. These 'dormant' cells are found in hypoxic regions of the tumor and may lead to disease relapse and poor prognosis.
Researchers found that metformin significantly increased tumor cell apoptosis and altered the cancer microenvironment in patients with head and neck cancer. The study suggests that metformin may make cancer more susceptible to standard therapies and has potential immunotherapeutic effects.
Researchers found inhibiting metabolic enzyme phosphoglycerate mutase 1 (PGAM1) sensitizes tumors to Olaparib, expanding cancer treatment options. Combining PGAM1 inhibitors with Olaparib suppresses tumor growth in BRCA-proficient cancers.
A study of 351 patients with EGFR mutant lung cancer and brain metastases found that radiation therapy followed by targeted medicines resulted in the longest overall survival, with median survival times of 46 months and 30 months respectively. The findings suggest that a more aggressive approach to treating brain metastases may be the ...
Researchers at Huntsman Cancer Institute identified a protein called Macrophage Stimulating Protein (MSP) that causes bone destruction in metastatic breast cancer. A new drug, Ron inhibitor, blocks the activity of MSP, showing promising results in early clinical trials.
Researchers identify proteins that interact with cancer-related proteins at the center of cellular signaling networks, potentially leading to new chemotherapies. These 'first neighbor' proteins have a significant impact on cancer progression and may be useful drug targets.
Researchers have discovered a common weak point in cancer cell metabolism, allowing them to identify drugs that block backup fuel supply routes. This strategy has shown promise against many hard-to-treat cancers, including sarcomas, and may lead to more effective treatments with fewer side effects.
UTA's integrated cancer research program is strengthening with $6 million grants, bolstering basic research, precision medicine, and screening diagnostics. The University aims to make transformative advances in key areas related to cancer while providing top-notch educational experiences for students.
Researchers found that breast cancer tumors evolve to produce their own estrogen supply, making treatments like aromatase inhibitors ineffective. The study, published in Nature Genetics, aims to increase treatment options for patients whose cancer has returned and spread.
Scientists at the University of North Carolina have discovered a promising new avenue for fighting gastrointestinal cancers by unmasking the previously misunderstood gene Gpr182. The study reveals that Gpr182 could be a key regulator of intestinal stem cell proliferation, and its protein code for a potential drug target.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
A new technique allows scientists to precisely regulate protein production from genes, enabling the design and study of biological systems. This breakthrough can be used to produce desired products, such as medicines, or study disease-related genes, including those implicated in cancer.
The European Society for Medical Oncology advocates for strict adherence to approval standards and accelerated introduction of biosimilars into clinical settings. This move aims to enhance the sustainability and affordability of cancer treatment, with potential benefits including reduced costs and increased accessibility.
Researchers at Case Western Reserve University have uncovered the structure of a cancer cell receptor protein, paving the way for the development of new cancer-fighting drugs. The study identified key binding sites that can be targeted to modulate the protein's function and prevent tumor growth and metastasis.
The DART trial is a national immunotherapy clinical trial testing leading-edge treatments for rare cancers. Patients will receive ipilimumab and nivolumab combination therapy to fight cancer, with the goal of shrinking tumors and evaluating side effects.
A phase 3 trial found regorafenib significantly improved overall survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer. The study showed that regorafenib can improve survival in patients whose HCC progressed during treatment with sorafenib, an existing drug.
The UK Pancreatic Cancer Research Fund has awarded £9 million in grants to five promising research projects aimed at developing new treatments and diagnostic tools for pancreatic cancer. These projects focus on improving clinical trials, investigating innovative therapies, and understanding the genetic causes of chromosomal instability.
A study by TGen has identified aurintricarboxylic acid (ATA) as a compound that can improve drug development against glioblastoma. ATA blocks the chemical cascade that allows glioblastoma cells to invade normal brain tissue and resist chemotherapy and radiation therapy.
A new drug combination that adds chloroquine to targeted treatment has stabilized a 26-year-old brain cancer patient's disease, increasing both quality and quantity of life. The treatment was effective in two other brain cancer patients with similar diseases.
Researchers at Mayo Clinic found that two common cancer-fighting drugs sparked significant weight loss in morbidly obese mice despite a high-fat diet. The study suggests that these drugs can induce the liver to burn off excess fat, reducing obesity. Further research is needed to explore this potential approach for treating morbid obesity.
Researchers found PDX1 plays a complex role in pancreatic cancer, maintaining cell identity in normal cells but contributing to growth once tumor forms. Blocking PDX1 may actually make the cancer more aggressive by selecting for MYC-expressing cells.
A new study reveals significantly better outcomes for patients with metastatic colorectal cancer when combining vemurafenib with standard treatments. The three-drug combination improved progression-free survival rates and tumor response rates compared to traditional therapies.
The Harrington Discovery Institute has selected three 2016 partnership scholars to support groundbreaking research in Alzheimer's disease and blindness. The scholars will receive funding and expert pharmaceutical guidance to advance their discoveries into new medicines.
The Harrington Discovery Institute has announced grant funding for 11 physician-scientists from premiere universities. The recipients will receive up to $700,000 in capital to support the transition of their work into the private sector.
Research in mice suggests that melanomas and other cancers driven by BRAF V600E mutation will grow faster in response to a high-fat diet. Lipid-lowering agents such as statins can slow tumor growth, even on normal diets. The findings highlight the potential of precision diets tailored to individual patients' cancer mutations.
Lutetium-177-Dotatate has shown improved progression-free survival and response rates compared to octreotide alone in patients with advanced disease. The treatment also experienced higher risk of adverse events, but these were manageable and reversible.
A novel treatment targets Graft-Versus-Host Disease (GVHD) by inhibiting Aurora kinase A and JAK2, preserving immune system function. The study shows promising results in mice, potentially offering a more effective and selective prevention strategy.
The Damon Runyon Cancer Research Foundation has awarded nearly $4 million in fellowships to 16 early-career researchers, providing them with independence to pursue innovative projects. The foundation's Breakthrough Scientist Awards also recognize three researchers who have made paradigm-shifting breakthroughs in cancer research.
A University of North Carolina researcher argues that integrating patient-reported symptoms into clinical practice can improve patient outcomes. Despite demonstrated benefits, cost and technology barriers prevent the widespread adoption of electronic symptom reporting.
Researchers at McGill University Health Centre have made a groundbreaking epigenetic modification that may improve treatment options for 15% of patients with head and neck cancer. The discovery could lead to targeted, more effective treatments with fewer side effects.
A Phase 1 clinical trial found that tucatinib significantly improved outcomes in heavily pretreated patients with HER2+ breast cancer. The drug demonstrated stable disease at 24 weeks or more in 27% of patients, showcasing its potential as a game-changing treatment option.
Researchers found that increasing niacin levels boosts NAD compound for energy generation and DNA repair, potentially protecting against Parkinson's. The study suggests repurposing cancer drugs to protect faulty mitochondria in Parkinson's disease.
Researchers have discovered that Dab2 controls a population of fat stem cells that slowly disappears with maturity. This finding may reinforce the importance of steering children away from high-fat diets and lead to new pharmaceutical strategies to combat childhood obesity.
A study found that adults who performed the recommended amount of weekly physical activity in one or two sessions had lower risks for death from all causes, cardiovascular disease, and cancer. The risk reductions were similar among weekend warriors and insufficiently active adults.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
A study published in JAMA Internal Medicine found that men and women who engage in physical activity on just one or two occasions per week have a lower risk of death from all causes, cardiovascular disease, and cancer. The 'weekend warriors' spent an average of 300 minutes per week doing moderate- to vigorous-intensity physical activity.
Researchers at the University Health Network have discovered a genetic fingerprint that explains why up to 30% of men with localized prostate cancer develop aggressive disease after radiotherapy or surgery. This finding could help clinicians personalize effective treatments from diagnosis, leading to improved cure rates.
Researchers found that tumors shed between seven and 18 mutations in neoantigen-coding genes after developing resistance to immunotherapy drugs. This phenomenon could lead to new ways to improve current cancer immunotherapies.